CureVac (NASDAQ:CVAC) Trading Up 7.5% – Should You Buy?

CureVac (NASDAQ:CVAC)’s stock price traded up 7.5% during mid-day trading on Friday . The stock traded as high as $3.05 and last traded at $3.08. 220,809 shares were traded during trading, a decline of 73% from the average session volume of 809,843 shares. The stock had previously closed at $2.86.

Analyst Upgrades and Downgrades

Separately, JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 price objective on shares of CureVac in a research note on Friday, February 14th.

CureVac Trading Up 11.5 %

The stock has a market capitalization of $714.18 million, a PE ratio of 5.80 and a beta of 2.48. The stock’s 50 day moving average price is $3.13 and its 200-day moving average price is $3.16. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05.

CureVac (NASDAQ:CVAC) last issued its quarterly earnings results on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). CureVac had a return on equity of 21.98% and a net margin of 20.72%. The business had revenue of $15.44 million during the quarter, compared to analysts’ expectations of $6.40 million. On average, sell-side analysts expect that CureVac will post 0.72 earnings per share for the current fiscal year.

Institutional Trading of CureVac

Several institutional investors and hedge funds have recently added to or reduced their stakes in CVAC. BNP Paribas Financial Markets bought a new stake in shares of CureVac during the fourth quarter valued at approximately $585,000. Two Sigma Investments LP purchased a new position in CureVac during the fourth quarter valued at $391,000. Alyeska Investment Group L.P. increased its holdings in CureVac by 25.0% in the 4th quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company’s stock valued at $1,705,000 after acquiring an additional 100,000 shares during the last quarter. Jane Street Group LLC lifted its stake in CureVac by 239.0% in the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock worth $235,000 after purchasing an additional 55,867 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of CureVac by 98.1% during the 4th quarter. Northern Trust Corp now owns 60,100 shares of the company’s stock valued at $205,000 after purchasing an additional 29,759 shares during the last quarter. Institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.